

QUANTITY LIMIT CRITERIA

BRAND NAME
(generic)**GRALISE**
(gabapentin extended-release tablet)**HORIZANT**
(gabapentin enacarbil extended-release tablet)**Status: CVS Caremark® Criteria****Type: Quantity Limit****POLICY****FDA-APPROVED INDICATIONS****Gralise**

Gralise is indicated for the management of postherpetic neuralgia.

Gralise is not interchangeable with other gabapentin products because of differing pharmacokinetic profiles that affect the frequency of administration.

Horizant**Treatment of Restless Legs Syndrome**

Horizant is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults.

Horizant is not recommended for patients who are required to sleep during the daytime and remain awake at night.

Management of Postherpetic Neuralgia

Horizant is indicated for the management of postherpetic neuralgia (PHN) in adults.

INITIAL LIMIT QUANTITY

Limits do not accumulate together; patient is allowed the maximum limit for each drug and strength

Drug	1 Month Limit*	3 Month Limit*
Gralise 300 mg (gabapentin extended-release)	150 tablets / 25 days	450 tablets / 75 days
Gralise 450 mg (gabapentin extended-release)	90 tablets / 25 days	270 tablets / 75 days
Gralise 600 mg (gabapentin extended-release)	90 tablets / 25 days	270 tablets / 75 days
Gralise 750 mg (gabapentin extended-release)	60 tablets / 25 days	180 tablets / 75 days
Gralise 900 mg (gabapentin extended-release)	60 tablets / 25 days	180 tablets / 75 days
Horizant 300 mg (gabapentin enacarbil extended-release)	60 tablets / 25 days	180 tablets / 75 days

Gralise, Horizant Limit Policy 3911-H 06-2023.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2023 CVS Health and/or its affiliates. All rights reserved. 106-58428B 021423

Horizant 600 mg
(gabapentin enacarbil extended-release)

60 tablets / 25 days

180 tablets / 75 days

**The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.*

REFERENCES

1. Gralise [package insert]. Morristown, NJ: Almatica Pharma LLC.; March 2023.
2. Horizant [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; April 2020.
3. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2023. <https://online.lexi.com>. Accessed April 20, 2023. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 04/20/2023).